ClinicalTrials.gov
ClinicalTrials.gov Menu

UARK 2009-32 Compassionate Use Study of Carfilzomib (2009-32)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00999414
Recruitment Status : No longer available
First Posted : October 21, 2009
Last Update Posted : October 26, 2015
Sponsor:
Collaborator:
Onyx Therapeutics, Inc.
Information provided by (Responsible Party):
University of Arkansas

Brief Summary:
This is a compassionate use, open-label, IND study for the purpose of providing carfilzomib to patients with relapsed or resistant refractory multiple myeloma.

Condition or disease Intervention/treatment
Multiple Myeloma Drug: Carfilzomib

Detailed Description:

The protocol has been designed for relapsing or refractory multiple myeloma patients. A maximum of 30 patients may be treated on this protocol.

Since this is a compassionate use study of an investigational agent, the size is determined by agreement with the manufacturer of carfilzomib. Therefore, the time period for enrollment and accrual number will be limited to N=30.


Study Type : Expanded Access
Official Title: Compassionate Use Study of Carfilzomib for Patients With Relapsing or Resistant Multiple Myeloma
Study Start Date : November 2009
Estimated Primary Completion Date : April 2015
Estimated Study Completion Date : April 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Multiple Myeloma
Drug Information available for: Carfilzomib
U.S. FDA Resources


Intervention Details:
    Drug: Carfilzomib

    Carfilzomib (20mg/m2) IV push to be given at maximum rate of 10ml/minute on Days 1 and Day 2 of Cycle 1 only.

    Carfilzomib (27mg/m2) IV bolus to be given at maximum rate of 10ml/minute on Day 8, 9, 15, and 16 of Cycle 1, then through Cycle 2 and beyond if initial dosing with 20mg/m2 tolerated.

    For patients who tolerated 27mg/m2 through cycle 2 Days 1 and 2, Carfilzomib dose may be escalated to 36mg/m2 on days 8, 9, 15 and 16 of cycle 2. If tolerated, subsequent cycles will utilize 36mg/m2.


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Participants must have histologically documented multiple myeloma which is relapsing or resistant after stem cell transplantation, or when other conventional therapies have failed or are contraindicated
  • Serum creatinine < 3.0 mg/dL OR calculated creatinine clearance >15 mL/min calculated or measured clearance is ≥15 mL/min
  • ANC > 1000/mm3 (may be supported with growth factors)
  • Platelet count > 30,000/mm3 (may receive transfusion)
  • Female participant of child-bearing potential has agreed to use dual methods of contraception for the duration of the study
  • Male participant has agreed to use a barrier method of contraception if sexually active with a female of child-bearing potential
  • Patients must have signed and IRB-approved written informed consent form and demonstrate willingness to meet follow-up schedule and study procedure obligations

Exclusion Criteria:

  • Active infection requiring systemic treatment
  • Requires concomitant use of approved or investigative anticancer therapeutic treatment with activity against multiple myeloma, other than dexamethasone
  • Concomitant use of other investigative agents (e.g., antibiotics or antiemetics)
  • Pregnant or breast-feeding

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00999414


Locations
United States, Arkansas
University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States, 72205
Sponsors and Collaborators
University of Arkansas
Onyx Therapeutics, Inc.
Investigators
Principal Investigator: Bart Barlogie, MD, PhD University of Arkansas

Additional Information:
Responsible Party: University of Arkansas
ClinicalTrials.gov Identifier: NCT00999414     History of Changes
Other Study ID Numbers: 111527
First Posted: October 21, 2009    Key Record Dates
Last Update Posted: October 26, 2015
Last Verified: October 2015

Keywords provided by University of Arkansas:
MM

Additional relevant MeSH terms:
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Neoplasms
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases